CSL Biotherapies begins shipping flu vaccine to U.S.
CSL Biotherapies plans to deliver approximately 11 million doses of the seasonal influenza vaccine to its U.S. clients for the upcoming flu season. The shipment will be made up of multi-dose and pre-filled syringe presentations.
"Given the magnitude of influenza burden in the U.S. and the unpredictability of seasonal outbreaks, timely delivery of flu vaccines is more critical now than ever before," Marie Mazur, CSL Biotherapies' head of worldwide commercial operations for influenza, said. "CSL Biotherapies is committed to addressing this public health need by consistently delivering its influenza vaccine early to the healthcare providers in the United States."
CSL Biotherapies is the U.S. headquarters of bioCSL, a company with the mission of delivering vaccines and protecting lives.
CSL Limited, the parent company of bioCSL and CSL Biotherapies, Inc., began manufacturing influenza vaccine in its Melbourne, Australia-based facility in 1968. CSL Limited recently made a $60 million investment in the Melbourne plant and its equipment to make it one of the largest vaccine manufacturing facilities worldwide.
CSL-branded influenza vaccines are approved for use in 28 countries.